David K H Webb

Summary

Affiliation: Great Ormond Street
Country: UK

Publications

  1. ncbi request reprint Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99
    David K H Webb
    Great Ormond Street Hospital for Children, London, Clinical Trial Service Unit, Oxford, UK
    Br J Haematol 117:33-9. 2002
  2. ncbi request reprint Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials
    Anupama Rao
    Department of Haematology, Camelia Botnar Laboratories, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 132:576-83. 2006
  3. ncbi request reprint Optimizing therapy for myeloid disorders of Down syndrome
    David K H Webb
    Department of Haematology, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 131:3-7. 2005
  4. ncbi request reprint Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia
    Emma C Morris
    Department of Haematology, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 120:787-9. 2003
  5. doi request reprint Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom
    Petra Temming
    Department of Paediatric Haematology, Great Ormond Street Hospital for Children, London, UK
    Pediatr Blood Cancer 56:625-30. 2011

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99
    David K H Webb
    Great Ormond Street Hospital for Children, London, Clinical Trial Service Unit, Oxford, UK
    Br J Haematol 117:33-9. 2002
    ..05). Allowing for cytogenetics, outcomes of therapy appear similar to those for de novo acute myeloid leukaemia (AML), and it is appropriate for children with RAEB/RAEBt to be registered in AML trials...
  2. ncbi request reprint Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials
    Anupama Rao
    Department of Haematology, Camelia Botnar Laboratories, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 132:576-83. 2006
    ..56%, P = 0.02). Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease...
  3. ncbi request reprint Optimizing therapy for myeloid disorders of Down syndrome
    David K H Webb
    Department of Haematology, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 131:3-7. 2005
    ..Accordingly, controlled dosage reduction is the focus of contemporary treatment studies...
  4. ncbi request reprint Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia
    Emma C Morris
    Department of Haematology, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 120:787-9. 2003
    ..02) and time from diagnosis to second CNS relapse (longer time was better, P = 0.004). Prognosis after second CNS relapse is extremely poor, and palliative therapy is appropriate...
  5. doi request reprint Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom
    Petra Temming
    Department of Paediatric Haematology, Great Ormond Street Hospital for Children, London, UK
    Pediatr Blood Cancer 56:625-30. 2011
    ....